Early cross-coronavirus reactive signatures of humoral immunity against COVID-19
| Autor: | Patrick Martin, Marcia B. Goldberg, Radosław P. Nowak, Michael R. Filbin, Moshe Sade-Feldman, Maricarmen Rojas-Lopez, Hargun K. Khanna, Chuangqi Wang, Brendan M. Lilley, Brenna N. McKaig, Brian C. Russo, Jaewon Kang, Yannic C. Bartsch, Anna L.K. Gonye, Nir Hacohen, Diana Dayal, Ching-Lin Hsieh, Boris Julg, Jessica Tantivit, Galit Alter, Kendall M. Lavin-Parsons, Stephanie Fischinger, Nicole C. Charland, Carl L. Lodenstein, Eric J. Nilles, Jason S. McLellan, Aaron G. Schmidt, Anil S. Menon, Kathryn Bowman, Justin D. Margolin, Douglas A. Lauffenburger, Jared Feldman, Elon R. Musk, Alexandra-Chloé Villani, Nihaarika Sharma, Thomas J. LaSalle, Eric S. Fischer, Paulina Kaplonek, Kasidet Manakongtreecheep, Matthew J. Gorman, Molly Thomas, Irena Gushterova |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
2019-20 coronavirus outbreak
Adolescent Coronavirus disease 2019 (COVID-19) viruses Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Immunology Receptors Fc Cross Reactions Biology medicine.disease_cause Article Cohort Studies Coronavirus OC43 Human Young Adult Mixed linear model medicine Humans Survivors Coronavirus SARS-CoV-2 Disease progression virus diseases COVID-19 General Medicine biochemical phenomena metabolism and nutrition Immunoglobulin Class Switching Virology Immunity Humoral Spike Glycoprotein Coronavirus Humoral immunity Correlation analysis Disease Progression |
| Zdroj: | bioRxiv article-version (status) pre article-version (number) 1 |
| ISSN: | 2470-9468 |
| Popis: | The introduction of vaccines has inspired hope in the battle against SARS-CoV-2. However, the emergence of viral variants, in the absence of potent antivirals, has left the world struggling with the uncertain nature of this disease. Antibodies currently represent the strongest correlate of immunity against SARS-CoV-2, thus we profiled the earliest humoral signatures in a large cohort of acutely ill (survivors and nonsurvivors) and mild or asymptomatic individuals with COVID-19. Although a SARS-CoV-2–specific immune response evolved rapidly in survivors of COVID-19, nonsurvivors exhibited blunted and delayed humoral immune evolution, particularly with respect to S2-specific antibodies. Given the conservation of S2 across β-coronaviruses, we found that the early development of SARS-CoV-2–specific immunity occurred in tandem with preexisting common β-coronavirus OC43 humoral immunity in survivors, which was also selectively expanded in individuals that develop a paucisymptomatic infection. These data point to the importance of cross-coronavirus immunity as a correlate of protection against COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|